News
2d
InvestorsHub on MSNAbbott Upgraded by Jefferies as Stock Selloff Seen as OverreactionAbbott Laboratories (NYSE:ABT) received an upgrade from Jefferies, which raised its rating to Buy from Hold, stating that the ...
Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...
3d
Zacks Investment Research on MSNAbbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales BeatAbbott Laboratories ABT reported second-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks ...
Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...
Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...
Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...
Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...
Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, ...
Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment & Supplies industry. Ideally ...
If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...
Abbott Laboratories stock rose 1.5% on Oct. 16 due to its strong Q3 earnings, where adjusted EPS of $1.21 beat estimates, reflecting a 6.1% increase from last year.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It March 24, 2025 — 09:00 am EDT Written by Zacks Equity Research for Zacks -> ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results